PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections 21 October
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level 01 October
